The American Society of Clinical Oncology (ASCO) has announced that the following guidelines, "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update Protocol" and “Initial Treatment for Chronic Lymphocytic Leukemia: ASCO Guideline Protocol,” are now open for public comment. These latest guidelines incorporate new evidence to ensure the most current recommendations are provided.
As part of ASCO's development process, they invite reviews and feedback for a 2- to 3-week period. Interested parties are encouraged to submit their comments here by April 28, 2025 at 11:59 PM EST. Your input is valuable in shaping the future of cancer management.
Copyright © 2025 Guideline Central, All Rights Reserved.